Jürgensen J H, Frederiksen J, Hansen D A, Pedersen-Bjergaard O
Br Heart J. 1981 May;45(5):583-8. doi: 10.1136/hrt.45.5.583.
Two hundred and eighty-two patients less than 66 years of age admitted with suspected or definite myocardial infarction were allocated in a random fashion to treatment with alprenolol or placebo. Treatment was started immediately upon admission with 5-10 mg alprenolol or placebo intravenously, followed by 200 mg alprenolol or placebo orally twice a day for one year. In 178 patients a definite myocardial infarction was diagnosed. Myocardial infarct size could be estimated from serial determinations of serum total creatine kinase in 42 patients treated with alprenolol and 43 patients receiving placebos. Median infarct size was 20.6 CK g Eq/m2 body surface in the alprenolol group, the corresponding figure in the placebo group being 34.4 CK g Eq/m2 body surface. Median rate of release of creatine kinase from the ischaemic myocardium was 27.7 U/1 per hour and 48.0 U/1 per hour after alprenolol and placebo, respectively. Alprenolol limited infarct size significantly provided the treatment was started within 12 hours of the onset of symptoms.
282名66岁以下因疑似或确诊心肌梗死入院的患者被随机分配接受阿普洛尔或安慰剂治疗。入院后立即开始治疗，静脉注射5 - 10毫克阿普洛尔或安慰剂，随后口服200毫克阿普洛尔或安慰剂，每日两次，持续一年。178名患者被诊断为确诊心肌梗死。42名接受阿普洛尔治疗的患者和43名接受安慰剂治疗的患者可通过连续测定血清总肌酸激酶来估计心肌梗死面积。阿普洛尔组梗死面积中位数为20.6 CK g Eq/m²体表面积，安慰剂组相应数字为34.4 CK g Eq/m²体表面积。阿普洛尔和安慰剂治疗后，缺血心肌肌酸激酶的中位数释放速率分别为每小时27.7 U/1和每小时48.0 U/1。如果在症状出现后12小时内开始治疗，阿普洛尔能显著限制梗死面积。
